Cargando…
SAT668 Can We Treat Osteoporosis, Obesity And Neurodegeneration With A Single FSH-blocking Drug?
Disclosure: A.R. Pallapati: None. J. Gimenez-Roig: None. S. Rojekar: None. F. Korkmaz: None. D. Sant: None. O. Barak: None. F. Sultana: None. O. Moldavski: None. A. Gumerova: None. H.S. Kannangara: None. U. Cheliadinova: None. C.J. Rosen: None. J.N. Caminis: None. M. Meseck: None. V.E. Demambro: Non...
Autores principales: | Rani Pallapati, Anusha Rani, Gimenez-Roig, Judit, Rojekar, Satish, Korkmaz, Funda, Sant, Damini, Barak, Orly, Sultana, Farhath, Moldavski, Ofer, Gumerova, Anisa, Kannangara, Hasni Suhasha, Cheliadinova, Uliana, Rosen, Clifford J, Caminis, John N, Meseck, Marcia, Demambro, Victoria Elise, Sims, Steven Lee, Gera, Sakshi, Witztum, Ronit, Miyashita, Sari, Ryu, Vitaly, Saxena, Mansi, Frolinger, Tal, Macdonald, Anne, Kim, Se-Min, Pevnev, Georgii, Lizneva, Daria, Yuen, Tony, Zaidi, Mone |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10554151/ http://dx.doi.org/10.1210/jendso/bvad114.116 |
Ejemplares similares
-
SAT669 Development And Biophysical Characterization Of A Humanized FSH-blocking Monoclonal Antibody Therapeutic Formulated At An Ultra-high Concentration
por: Rojekar, Satish, et al.
Publicado: (2023) -
FRI001 Tanycytic Thyroid-stimulating Hormone Receptor Activation Increases Blood-Hypothalamus Barrier Permeability And Induces Appetite In Female Mice
por: Kannangara, Hasni Suhasha, et al.
Publicado: (2023) -
SAT649 Org43553, The First Low-molecular-weight Agonist Of The Human Luteinizing Hormone Receptor Induces Leanness And Energy Expenditure In Mice
por: Lizneva, Daria, et al.
Publicado: (2023) -
Development and Biophysical Characterization of a Humanized FSH–Blocking Monoclonal Antibody Therapeutic Formulated at an Ultra–High Concentration
por: Rojekar, Satish, et al.
Publicado: (2023) -
Development and biophysical characterization of a humanized FSH–blocking monoclonal antibody therapeutic formulated at an ultra-high concentration
por: Rojekar, Satish, et al.
Publicado: (2023)